Lipotec, S.a.

Bcn Peptides S.a.

Gp Pharm, S.a.

Laboratorio Reig Jofre, S.a.

Antonio Parente Dueña

Berta Ponsati Obiols

Josep Garces Garces

Jimena Fernández Carneado

Josep Farrera-Sinfreu

Marc Gómez Caminals

Francesca Reig Isart

Antonio Boix Montanes

Jesus Guinea Sanchez

Ricardo Casaroli Marano

Manuel Reina Del Pozo

Ricard Mis Vizcaino

Senen Vilaro Coma

María Dolores Polo Trasancos

Nuria Carbajal Navarro

Jimena Fernandez Carneado

Josep Maria Garcia Anton

Carlos Nieto Abad

Angel Bonilla Muñoz

Ruben Martin Laguens

David Cunillera Colomé

Ribera Jordana I Lluch

Cesar Garcia Plumed

Ferran Pons Lambiez

Josep Garcés Garcés

Angels Fabra Fres

Marc Gomez Caminals

Moises Gabriel Zeitune

Jimena FERNÁNDEZ Carneado

Claudio Savulsky

The invention relates to cortistatin analogues and their uses. The compounds of the invention are peptide ligands with potential application in the diagnosis, prevention or therapy of those pathologies where receptors capable of binding to cortistatin, specific or shared with other molecules such as somatostatin and/or ghrelin (GHSR), are expressed, being in addition more stable in serum than cortistatin.

Cortistatin analogues for the treatment of inflammatory and/or immune diseases

Micro-capsules for the slow release of drugs, consisting of a lactic-co-glycolic copolymer to which a plasticizer has been incorporated and which contain a drug of pharmaceutical interested within them.

Method for delivering a peptide to a subject at a modulated rate via microcapsules of lactic-co-glycolic copolymer containing said peptide

The present invention relates to a liquid oral pharmaceutical composition of desmopressin, and its use for the treatment of central diabetes insipidus, primary nocturnal enuresis, bleeding in patients with Hemophilia A, with von Willebrand-J&#xfc;rgens disease and postoperative bleeding.

Oral pharmaceutical composition of desmopressin

Peptide derivatives, their stereoisomers, mixtures thereof and/or their pharmaceutically acceptable salts, a method of obtaining them, pharmaceutical compositions containing them and the use thereof for the treatment, prevention and/or diagnosis of those conditions, disorders and/or pathologies in which the sstr1, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptors are expressed.

Peptide ligands of somatostatin receptors

Liposomes encapsulating anticancerous drugs and the use thereof in the treatment of malignant tumors. The liposomes are coated with a lipopeptide composed of three substructures: a lipid fragment, an active oligopeptide and an oligopeptide spacer between the other two fragments. Applicable in intravenous administration for treatment of malignant tumors.

Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumors

Use of a glycoprotein produced byand consisting of 14% carbohydrates and 86% protein in the preparation of pharmaceutical, veterinary and cosmetic compositions for topical or mucous application in the treatment and re-epithelialization of wounds and in the preparation of cosmetic compositions for treatment of skin, hair or nails.

Use of a glycoprotein for the treatment and re-epithelialisation of wounds

Growing community of inventors

Barcelona, Spain

Antonio Parente Dueña